[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mesenchymal-stem-cell\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mesenchymal-stem-cell":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":4},"100582367","phase-1-stem-cell-therapy-for-intracerebral-hemorrhage-100582367",false,"NCT06862388","Stem Cell Therapy for Intracerebral Hemorrhage","Clinical Research on Umbilical Cord Mesenchymal Stem Cells Therapy for Patients With Subacute Intracerebral Hemorrhage","Inclusion Criteria:\n\n1. Age 18-65 years old, gender is not limited.\n2. Clinically confirmed intracerebral hemorrhage during the subacute period (3 days-10 days after onset).\n3. CT confirmed as cerebral parenchymal hemorrhage, ABC\u002F2 method to calculate the episodic hemorrhage volume of 15-30 mL (ABC\u002F2 method hematoma volume calculation formula V (cm3) =A×B×C×1\u002F2, A is the longest diameter of the largest level of the hematoma in the horizontal position of the CT scan (cm), B is the widest diameter of the hematoma in this plane perpendicular to the A (cm), C is the thickness of the hematoma appearing in the CT film (cm)).\n4. Blood biochemical indexes meet the following conditions: 1) good coagulation function, international normalized ratio (INR) \\\u003C2; 2) alachlor aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 times the upper limit of the normal value, and total bilirubin \\\u003C2 times the upper limit of the normal value; 3) creatinine clearance \\>50 mL\u002Fmin; 4) hemoglobin \\>90 g\u002FL; 5) absolute neutrophil value (ANC) ≥ 1.5×10\\^9\u002FL, absolute lymphocyte count ≥0.4×10\\^9\u002FL, platelet count ≥80×10\\^9\u002FL, and albumin \\>25g\u002FL; 6) procalcitonin (PCT) ≤2ng\u002FmL.\n5. National Institutes of Health Stroke Scale score (NIHSS) ≥5 and ≤20.\n6. Pre-onset modified Ranking Scale score (mRS) ≤1.\n7. Glasgow Coma Score (GCS) ≥9 points and ≥3 points on a single item.\n8. Good compliance, signed informed consent by the person and\u002For legal guardian and able to receive follow-up visits at the specified time.\n\nExclusion Criteria:\n\n1. Brain midline deviation \\>10 mm or brain hernia formation.\n2. Patients who have undergone or intend to undergo surgical treatment to remove hematoma.\n3. Secondary intracerebral hemorrhage caused by traumatic brain injury, arteriovenous malformation, intracranial aneurysm, coagulation disorders, hemorrhagic transformation after cerebral infarction, or tumors.\n4. Suffering from malignant tumors, autoimmune diseases (including but not limited to systemic lupus erythematosus, systemic vasculitis, etc.), hemorrhagic predisposition diseases (including all kinds of hereditary hemorrhagic disorders and acquired hemorrhagic diseases), malignant cardiac arrhythmia, cardiac insufficiency (BNP ≥1000pg\u002FmL or left ventricular ejection fraction ≤40%), acute myocardial infarction, acute or severe infectious diseases (such as intracranial infection, severe pneumonia, sepsis, etc.) and other serious diseases that may aggravate the condition and affect the assessment of efficacy.\n5. Allergy or intolerance to stem cell preparations or related medicines that need to be used in the infusion process, such as saline preparations and hormone preparations.\n6. Pregnant or lactating women.\n7. History of stroke disease with sequelae in the last 1 year, NIHSS score ≥ 6.\n8. Subarachnoid hemorrhage, primary ventricular hemorrhage, pharmacological hemorrhagic stroke.\n9. Unstable vital signs, including combined respiratory abnormalities (respiratory rate \\\u003C12 breaths\u002Fmin or \\>24 breaths\u002Fmin, oxygen saturation ≤90%), hyperthermia (axillary temperature \\>39 ℃), blood pressure ≥180\u002F100 mmHg after antihypertensive treatment, blood glucose \\>20 mmol\u002FL.\n10. Those who are participating in other clinical trials.\n11. Previous history of epilepsy or current use of antiepileptic drugs.\n12. Unable to accept all laboratory tests and imaging tests designed by the program due to metal implants or pacemakers in the body.\n13. Inability to complete the follow-up program as required.\n14. Patients or their legal guardians are unwilling to sign the written informed consent.","ALL","18 Years","65 Years",{"count":20,"type":21},39,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Intracerebral hemorrhage (ICH) is a common condition with high morbidity, mortality, and disability. The current treatments for ICH primarily include surgical and pharmacological interventions. For large hematomas, surgical options such as craniotomy, debridement, decompression, and minimally invasive hematoma aspiration may be performed. Pharmacological treatments are mainly symptomatic. Despite timely and standardized surgical or pharmacological interventions, many patients with ICH still experience significant sequelae, which severely affect their quality of life and place a substantial burden on both families and society. Currently, there are limited drugs available specifically for the treatment of ICH.\n\nIn recent years, stem cell therapy has gained attention as a promising treatment for neurological diseases. Human umbilical cord mesenchymal stem cells (UC-MSCs) are multifunctional stem cells with properties such as self-renewal, multidirectional differentiation potential, tissue repair, immunomodulation, and anti-inflammatory effects. Studies have shown that intravenous transplantation of UC-MSCs is safe, and their application in the treatment of ICH can reduce hematoma volume, attenuate cerebral edema and inflammation, and promote the recovery of neurological function. These findings offer a novel therapeutic strategy for ICH.\n\nThe purpose of this clinical trial is to evaluate the safety and efficacy of UC-MSCs transplantation in patients with subacute intracerebral hemorrhage, and providing a potential new therapeutic approach for this challenging condition.",[28,29],"Intracerebral Hemorrhage","Mesenchymal Stem Cell",[31,32,33,34,35],"Intracerebral hemorrhage","Human umbilical cord mesenchymal stem cells","Stem cell therapy","Inflammation","Neural repair","NOT_YET_RECRUITING","2025-03-02",{"date":39,"type":40},"2025-03-06","ACTUAL",{"date":42,"type":21},"2025-03-01",{"date":44,"type":21},"2027-07-31",{"name":46,"class":47},"Tang Zhouping","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100579536","phase-1-msc-evs-in-acute-acute-on-chronic-liver-failure-after-liver-transplantation-100579536","NCT06825572","MSC-EVs in Acute\u002F Acute-on-Chronic Liver Failure After Liver Transplantation","Mesenchymal Stem Cells-Derived Extracellular Vesicles (MSC-EV) in Acute\u002FAcute-on-Chronic Liver Failure After Liver Transplantationa：a Prospective, Randomized, Controlled Clinical Study","Inclusion Criteria:\n\n* aged 18-70 years;\n* Acute on chronic liver failure-which is characterized by acute hepatic insult manifesting as jaundice (serum total bilirubin \\[TBil\\] ≥ 10×ULN umol\u002FL) and coagulopathy (international normalized ratio \\[INR\\] ≥ 1.5 or prothrombin activity \\\u003C 40%), complicated within 4 weeks by ascites and\u002For encephalopathy as determined by physical examination, in patients with previously diagnosed or undiagnosed chronic liver disease; Requiring liver transplantation due to acute on chronic liver failure;\n* Obtain the patients' consent after informing patients of the purpose and method of the clinical trial;\n\nExclusion Criteria:\n\n* Past history of malignant disease\n* Active uncontrolled infection;\n* Combined transplantation\n* EBV-negative;\n* HIV or HCV positive;\n* Retransplantation;","70 Years",{"count":57,"type":21},30,[24],"Acute liver failure (ALF) refers to a potentially reversible disorder that was the result of severe liver injury, with an onset of encephalopathy within 8 weeks of symptom appearance and in the absence of pre-existing liver disease. Acute-on-chronic liver failure refers to a liver failure syndrome in which some patients with chronic liver disease with relatively stable liver function suffer from acute liver decompensation and liver failure due to the effects of various acute injury factors. Liver transplantation is the only curative treatment for this type of end-stage liver disease. The potential of MSCs to repair or regenerate damaged tissue and suppress immune responses makes them promising in the treatment of liver diseases, especially in the field of liver transplantation. Many studies have shown that MSC-based therapies can reduce the symptoms of liver disease due to their paracrine effects. Therefore, compared to the cells they derive from, mesenchymal stem cells-derived extracellular vesicles (MSC-EV) are gradually gaining attention for their enhanced safety, as they do not replicate or cause microvascular embolism, and can be easily stored without losing their properties. It represents a novel and effective cell-free therapeutic agent as alternative to cell-based therapies for liver diseases, and liver failure was also concerned. This study was designed to evaluate the safety and tolerability of MSC-EV in acute-on-chronic liver failure after liver transplantation.",[61,29,62],"Liver Failure","Extracellular Vesicles",[64,65,66],"MSC-EV","Liver transplantation","Liver failure","2025-02-09",{"date":69,"type":40},"2025-02-13",{"date":71,"type":21},"2025-04-01",{"date":73,"type":21},"2026-09-30",{"name":75,"class":47},"Third Affiliated Hospital, Sun Yat-Sen University",1]